Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601107 | 0.84 | HCAR1 (0.41) | HCAR1CYP3A4ACHECA1CA12 | |
| SCHEMBL27112161 | 0.84 | HCAR1 (0.41) | HCAR1CYP3A4ACHECA1CA12 | |
| SCHEMBL288979 | 0.81 | CES2 (0.46) | HCAR1CA1CA2HPGDHSD17B10 | |
| SCHEMBL28888036 | 0.81 | AKR1C2 (0.45) | HCAR1CA1CA12CA9CA2 | |
| SCHEMBL542833 | 0.79 | LMNA (0.50) | HCAR1CA1CA12CA9CA2 | |
| SCHEMBL29154306 | 0.79 | CES2 (0.44) | HCAR1CA1CA2HPGDHSD17B10 | |
| SCHEMBL17177745 | 0.79 | AKR1C2 (0.44) | HCAR1CA1CA12CA9CA2 | |
| SCHEMBL29025457 | 0.78 | ESR1 (0.44) | MIF | |
| SCHEMBL257644 | 0.77 | CA1 (0.34) | HCAR1CYP3A4ACHECA1CA12 | |
| SCHEMBL3031058 | 0.77 | TPMT (0.48) | HCAR1CYP3A4HPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178685-A | LCP material with high clearing point and preparation method thereof | 宁夏清研高分子新材料有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-113004694-A | Organic silicon material capable of being ceramized and preparation method thereof | 西南科技大学 | 2021-06-22 | — | — | CN | claimed |
| JP-10265442-A | — | — | None | — | — | JP | disclosed |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-119463143-A | Polynaphthalate resin and preparation method thereof | 四川大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-1441031-A | Liquid crystal polyester resin composition for connector | SUMITOMO CHEMICAL CO (JP) | 2003-09-10 | — | — | CN | disclosed |
| US-6512079-B2 | Acylating aromatic diol and/or aromatic hydroxycarboxylic acid with fatty anhydride, then transesterifying, in presence of imidazole based compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020143135-A1 | Process for producing aromatic liquid crystal polyester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20020055607-A1 | Liquid crystalline polyester and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1184401-A1 | Liquid crystalline polyester and method for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-06 | — | — | EP | disclosed |
| JP-H10265442-A | DIFLUOROBENZOIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | CHISSO CORP | 1998-10-06 | — | — | JP | disclosed |
| US-4857626-A | OPTICAL,ANISOTROPIC POLYMERS; HEAT RESISTANCE MOLDING MATERIALS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| US-4814417-A | Process for producing a liquid crystalline polyester polymer of a cyclohexanedicarboxylic acid and an aromatic diol with pyridine/thionyl chloride catalyst | CHISSO CORPORATION (JP) | 1989-03-21 | — | — | US | disclosed |
| EP-0272676-A2 | Wholly aromatic polyester and process for its production | Mitsubishi Chemical Corporation (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | HCAR1 3141/4885CYP3A4 1340/4885ACHE 1476/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | HCAR1 805/4885CYP3A4 2737/4885ACHE 4865/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | HCAR1 3141/4885CYP3A4 1340/4885ACHE 1476/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | HCAR1 3141/4885CYP3A4 1340/4885ACHE 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.